CRESCENT BIOPHARMA, INC. Shareholders' Equity
CRESCENT BIOPHARMA, INC. (CBIO) had Shareholders' Equity of $163.25 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-30
- 2026-06-30: Stockholders' Equity Attributable to Parent $163.25M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $183.85M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $203.01M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $116.64M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $163.25M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $183.85M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $203.01M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $116.64M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $139.25M 10-Q · filed 2026-07-30 | |
| 2025-03-31 | -$30.16M 10-Q · filed 2026-07-30 | $3.38M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$15.48M 10-Q · filed 2026-07-30 | $5.31M 10-K · filed 2025-02-13 |
| 2024-09-30 | -$1.30M 10-Q · filed 2025-11-06 | $11.38M 10-Q · filed 2024-11-13 |
| 2024-09-19 | $0.00 10-K · filed 2026-02-26 | |
| 2024-06-30 | $20.06M 10-Q · filed 2024-11-13 | |
| 2024-03-31 | $28.91M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $38.41M 10-Q · filed 2025-05-14 | |
| 2023-09-30 | $46.55M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $54.80M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $62.18M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $42.93M 10-K · filed 2025-02-13 | |
| 2022-09-30 | $48.12M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $55.73M 10-Q · filed 2023-11-03 | |
| 2022-03-31 | $68.03M 10-Q · filed 2023-11-03 | |
| 2021-12-31 | $81.60M 10-K · filed 2024-03-27 | |
| 2021-09-30 | $96.57M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $112.29M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $125.12M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $128.22M 10-K · filed 2024-03-27 | |
| 2020-09-30 | $138.27M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $145.75M 10-Q · filed 2021-11-02 | |
| 2020-03-31 | $148.49M 10-Q · filed 2021-11-02 | |
| 2019-12-31 | $154.20M 10-K · filed 2023-03-29 | |
| 2019-09-30 | $167.08M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $178.56M 10-Q · filed 2020-11-06 | |
| 2019-03-31 | $192.79M 10-Q · filed 2020-07-31 | |
| 2018-12-31 | $205.46M 10-K · filed 2022-03-03 | |
| 2018-09-30 | $218.10M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $227.99M 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $238.04M 10-Q · filed 2019-08-01 | |
| 2017-12-31 | $119.70M 10-K · filed 2021-03-02 | |
| 2017-09-30 | $108.56M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $115.43M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $31.89M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $35.30M 10-K · filed 2020-02-28 | |
| 2016-09-30 | $41.75M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $48.88M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $34.77M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $40.47M 10-K · filed 2019-03-06 | |
| 2015-09-30 | $48.70M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $55.22M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $44.36M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $50.80M 10-K · filed 2018-03-06 | |
| 2014-09-30 | $57.71M 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $63.88M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $55.35M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $2.91M 10-K · filed 2017-03-01 | |
| 2012-12-31 | $12.53M 10-K · filed 2016-02-29 | |
| 2011-12-31 | $8.46M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |